Increasing diversity in myeloma clinical trials: addressing disparities & inclusion criteria

Craig Cole, MD, Karmanos Cancer Institute, Detroit, MI, discusses the need for more inclusive clinical trials in multiple myeloma, emphasizing the underrepresentation of Black and African American patients, as well as Hispanic patients. Dr Cole highlights specific challenges, such as exclusion criteria linked to the Duffy null phenotype, which disproportionately impacts Black patients, and suggests solutions including decentralized trials and revised inclusion criteria. This interview took place at the 21st International Myeloma Society (IMS) Annual Meeting, held in Rio de Janeiro, Brazil.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.